This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stocks to Watch for a Potential Kamala Harris Presidency
by Shaun Pruitt
Let's discuss a few stocks and sectors that should be kept in mind for a potential Kamala Harris presidency as opposed to the Biden or Trump trade.
Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Organon (OGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Organon (OGN) stood at $20.81, denoting a +0.39% change from the preceding trading day.
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $19.93, indicating a -1.04% shift from the previous trading day.
Do Options Traders Know Something About Organon (OGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
Organon (OGN) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $20.63, indicating a -0.77% shift from the previous trading day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Encompass Health (EHC) Gains 30% in a Year: More Room to Run?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of sustained top-line growth, an aging U.S. population, frequent expansion initiatives and strong cash reserves.
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
Humana's (HUM) CenterWell Expands in Louisiana With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.
Organon (OGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Organon (OGN) closed the most recent trading day at $20.45, moving +0.49% from the previous trading session.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Compelling Reasons to Hold on to HCA Healthcare (HCA) Stock
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ensign Group (ENSG) Buys Facilities in Arizona & Colorado
by Zacks Equity Research
Ensign Group (ENSG) expands its footprint by acquiring skilled nursing facilities in Arizona and Colorado, enhancing its healthcare services and real estate portfolio.
Organon (OGN) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Tenet Healthcare (THC) Gains 89% in a Year: More Room to Run?
by Zacks Equity Research
Tenet Healthcare (THC) is well-poised to gain from improved volumes, expansion of specialty services, streamlining operations and operational efficiency.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
by Zacks Equity Research
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Centene (CNC) Expands CHS Network, Shifts AcariaHealth Facility
by Zacks Equity Research
Centene's (CNC) subsidiaries, CHS and AcariaHealth, enhance patient outcomes with CHS' CIPA entering Virginia and AcariaHealth's pharmacy facility relocating to Chesterfield, thereby expanding CNC's capabilities.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Zacks.com featured highlights include Vital, Sprouts Farmers, Royal Caribbean, Agnico and Organon
by Zacks Equity Research
Vital, Sprouts Farmers, Royal Caribbean, Agnico and Organon have been highlighted in this Screen of The Week article.
5 Relative Price Strength Stocks With Strong Return Potential
by Nilanjan Choudhury
VITL, SFM, RCL, AEM and OGN are five stocks with explosive relative price strength.
Why You Should Add Encompass Health (EHC) to Your Portfolio Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.